<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>101-BRENTUXIMAB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BRENTUXIMAB " rxcui="1147320">
<ATC code="L01XC12" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BLEOMYCIN " rxcui="1622">
<ATC code="L01DC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of pulmonary toxicity</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>101-BRENTUXIMAB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="BRENTUXIMAB " rxcui="1147320">
<ATC code="L01XC12" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the concentrations of the active metabolite of the brentuximab, with risk of neutropenia</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
</INTERACTIONS>
